Dr. Susan Borghoff is based in Research Triangle Park, NC. She is a board-certified toxicologist with over 30 years of experience designing and managing diverse research programs and regulatory-driven in vitro and in vivo toxicology studies for commercial and federal clients. Her work has also included scientific and technical oversight, data analysis and interpretation, and preparation of both Final GLP Study Reports for regulatory submission and peer-reviewed scientific manuscripts. Dr. Borghoff has directed scientific research to support dose-response and hazard identification for incorporation into human health risk assessments.
Dr. Borghoff is a recognized expert in evaluating modes of action by which agents cause toxicity, modulate endocrine pathways, and cause cancer in rodents, and the relevance of these responses for assessing human risk. Her research has focused on understanding the metabolism and pharmacokinetics of agents using physiologically based pharmacokinetic (PBPK) models for extrapolation of risk to humans. She has been involved with critical reviews of toxicity and carcinogenicity studies, advising on specific study designs to fill data gaps for understanding modes of action, and as an Expert Panel member for scientific oversight of industry-sponsored toxicity and carcinogenicity testing programs. Dr. Borghoff’s experience also includes implementing a program to conduct GLP regulatory studies associated with the US Environmental Protection Agency (USEPA)-mandated Endocrine Disruption Screening Program (EDSP) and co-chairing a workshop titled, “Lessons Learned, Challenges, and Opportunities: The US Endocrine Disruptor Screening Program,” held in Research Triangle Park in 2013 to assess this program.
Over the last 8 years, Dr. Borghoff has been involved in the development of various biological (e.g., monoclonal antibodies) and small-molecule products for different disease indications, such as rheumatoid arthritis, NASH, solid tumors, and diabetic foot infections, etc. She also has experience in the design, monitoring, and interpretation of nonclinical toxicology and pharmacology studies (GLP and non-GLP), and has written the nonclinical sections of investigational new drug (IND) applications for both biopharmaceutical and pharmaceutical agents.
Dr. Borghoff has served as a reviewer on a number of panels/working groups for international organizations, including USEPA, National Cancer Institute, International Programme on Chemical Safety (IPCS), European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC), and three Monograph Working Groups (vol. 73, 77, and 82) of the International Agency for Cancer Research (IARC), and most recently as an Observer for Monograph vol.115, Some Industrial Chemicals. She was also an observer at the advisory group meeting to recommend priorities for the IARC Monographs during 2020–2024 (March, 2019). She has been a reviewer for various grants through NIH, NIEHS, and USEPA and has been a panel member on the Voluntary Children’s Chemical Evaluation Program (VCCEP) review of ethylbenzene.
Dr. Borghoff received the Frank R. Blood Award in 1994 for the best paper of the year published in a Society of Toxicology research journal, and a Society of Toxicology Risk Assessment Specialty Section Award in 2000. She is a member of the North Carolina Chapter of the Society of Toxicology, and at the national level, has served on SOT Council, as well as various committees (e.g., Program, Awards, Education Committees). Most recently, Dr. Borghoff was a member of the SOT’s TSCA Reform Task Force and was the Audit Committee Co-Chair. She has also served as an Associate Editor for Toxicological Sciences, along with other editorial positions for several scientific journals, and is currently on the editorial board of the International Journal of Toxicology.
Dr. Borghoff received her Ph.D. and MSPH in Environmental Sciences and Engineering from the University of North Carolina, and a B.S. in Chemistry from East Stroudsburg University in Pennsylvania. Dr. Borghoff became a Diplomate of the American Board of Toxicology in 1994.